Trikafta 80-40-60MG/59.5MG PKT 14S
Ended Awarded
- Contract number
- SPE2DB25FPRM7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $337,658
Award facts
- Contract value 100% obligated
- $337,657.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $337,657.98 by the Defense Logistics Agency (DLA) on September 17, 2025. The contract calls for the delivery of Trikafta 80-40-60 mg/59.5 mg packets in quantities of 14, with an ultimate completion date of September 18, 2025. This delivery order was issued without a set-aside designation and represents performance at the vendor's Park Ridge, Illinois facility. The award is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA valued at $499,999,999 and valid through November 2026, which authorizes the agency to issue firm fixed-price delivery orders for pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
Trikafta is a prescription medication used in the treatment of cystic fibrosis, demonstrating the specialized pharmaceutical nature of DMS Pharmaceutical Group's federal contracting portfolio. As a crucial supplier within the federal pharmaceutical supply chain, the company has established a robust track record delivering prescription medications, biologics, and medical consumables to military and federal healthcare facilities. The DLA's pharmaceutical procurement through this IDC vehicle enables efficient distribution of critical medications to Department of Defense healthcare sites across the globe, leveraging DMS Pharmaceutical Group's established capabilities as an authorized pharmaceutical wholesaler serving the federal government.
Quick answers
Who was awarded contract SPE2DB25FPRM7?
SPE2DB25FPRM7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 17, 2025.
How much is contract SPE2DB25FPRM7 worth?
The government has obligated $337,658 on SPE2DB25FPRM7.
Is contract SPE2DB25FPRM7 an order under another contract?
Yes. SPE2DB25FPRM7 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPRM7 competed?
The extent of competition for SPE2DB25FPRM7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award